Efficacy and safety of ²²⁵Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study.

ABSTRACT:

Purpose

In this study, we aim to evaluate the efficacy and safety of ²²⁵AC-DOTATATE targeted alpha therapy in advanced-stage paragangliomas (PGLs).

Methods

Nine (6 males and 3 females) consecutive patients with histologically proven PGLs were treated with ²²⁵Ac-DOTATATE targeted alpha therapy (TAT) and concomitant radiosensitizer, capecitabine, at 8-weekly intervals up to a cumulative activity of ~ 74 MBq. The primary endpoint included evaluating therapy response and disease control rate (DCR) using the RECIST 1.1 criteria. Additional secondary endpoints comprised clinical response assessment using EORTC QLQ-H&N35 questionnaire, Karnofsky Performance Scale (KPS), Eastern Cooperative Oncology Group performance status (ECOG), analgesic score (AS), dose al

SUBMITTER: Yadav MP 

PROVIDER: S-EPMC8626283 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature